April 6, 2026
Perspective Therapeutics CEO Thijs Spoor on developing alpha-emitting radiotherapies, the primacy of biodistribution, and scaling production.
March 30, 2026
Yosemite's Dan McHugh discusses a unique VC model blending academic grants and investments to accelerate early-stage oncology innovation.
March 23, 2026
Legend Biotech's Alan Bash shares insights on Carvicti's blockbuster success, the power of strategic partnerships, and next-gen CAR-T.
March 16, 2026
Plus Therapeutics pioneers novel radiotherapeutics and diagnostics to combat historically intractable CNS cancers like glioblastoma and LM disease.
March 9, 2026
Iterion Therapeutics' CEO discusses a capital-efficient strategy for developing novel cancer drugs by targeting the "undruggable" Wnt pathway.
March 2, 2026
Vivtex CEO Thomas von Erlach on developing orally available biologics, spinning out of Langer's lab, and securing a $2.1B Novo Nordisk deal.
Vivtex CEO Thomas von Erlach on creating oral biologics, securing a $2.1B Novo Nordisk deal, and leveraging a platform-first strategy.
February 23, 2026
Applying anthropology to biotech: Dr. Monika Sumra explains how environment shapes leadership and performance, urging leaders to fix systems, not people.
February 16, 2026
Seek Labs' CEO Jared Bauer on company turnarounds and leveraging a full-stack AI platform for CRISPR therapeutics and diagnostics for infectious disease.
February 9, 2026
Kite Pharma's Cindy Perettie discusses scaling curative CAR-T therapies, the necessity of partnerships, and advancing patient access beyond major centers.
February 2, 2026
Boehringer Ingelheim's US President Brian Hilberdink on leveraging private ownership for long-term innovation, commercial strategy, and obesity.
January 26, 2026
enGene CEO Ron Cooper on scaling biotechs, creative fundraising, strategic storytelling, and navigating from R&D to global commercialization.
January 19, 2026
Airway Therapeutics' CEO Marc Salzberg on developing zelpoltide alpha for BPD, bridging academia-industry gaps, and navigating Phase 3 funding.
January 12, 2026
Zymeworks CEO Kenneth Galbraith discusses leveraging partnerships, long-term value, and a new royalty model for biotech success.
January 5, 2026
Biotech editors recap 2025's funding winter and FDA shakeup, forecasting 2026's focus on AI, GLP-1s, RNA therapies, and China's rise.
December 29, 2025
Kenai Therapeutics CEO Nick Manusos on building a company around an iPSC therapy for Parkinson's, from spin-out to funding and clinical trials.
December 22, 2025
Merck's Jennifer Sheller discusses modernizing clinical trials through lean protocols, risk-based quality management, and a hybrid FSP model.
December 15, 2025
ProKidney CEO Bruce Culleton discusses disrupting chronic kidney disease (CKD) with autologous cell therapy to delay or eliminate dialysis.
December 8, 2025
Immusoft CEO Sean Ainsworth on pioneering re-dosable B-cell therapies, his journey from the Navy to biotech, and lessons in fundraising & exits.
December 1, 2025
Actuate Therapeutics CEO Dan Schmitt discusses developing a novel cancer drug, leading through a tough market, and efficient, lean operations.
November 17, 2025
Biotech funding is recovering, fueled by M&A and a potential IPO revival. Success hinges on quality, strategic timing, and capital discipline.
November 10, 2025
Madrigal CFO Marty Dier on launching the first MASH drug, transitioning from R&D to commercial, and navigating biotech capital markets.
